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In the European Society of Cardiology 2014 guidelines on hypertrophic cardiomyopathy (HCM), exercise stress echo 
6(LVUHFRPPHQGHGLQV\PSWRPDWLFSDWLHQWVLIEHGVLGHPDQRHXYUHVIDLOWRLQGXFHOHIWYHQWULFXODURXWÀRZWUDFWJUDGLHQW
/927*PP+JDQGLVUDWHGDVFODVV,OHYHORIHYLGHQFH%7KHUHFRPPHQGDWLRQLVFODVV,,EOHYHORIHYLGHQFH&
in asymptomatic patients. This evidence-based approach uses one stress (exercise), one parameter (LVOTG), and one 
target (obstruction) in one HCM patient (symptomatic without obstruction at rest). However, the omnivorous versatility 
of contemporary SE appears ideally suited to unmask the functional heterogeneity underlying the similar morphology 
and clinical presentation of HCM. At least 7 parameters converge conceptually, logistically, and methodologically in the 
ABCDEFG-SE protocol in HCM. They are: 1) regional wall motion abnormalities (step A); 2) B-lines by lung ultrasound 
(step B), possibly with other indices of diastolic function such as E/e' and systolic pulmonary arterial pressure (from 
WULFXVSLGUHJXUJLWDQWMHWYHORFLW\RUDFFHOHUDWLRQWLPHRIIRUZDUGV\VWROLFSXOPRQDU\ÀRZOHIWYHQWULFXODUFRQWUDFWLOH
DQGSUHORDGUHVHUYHVWHS&EDVHGUHVSHFWLYHO\RQIRUFHV\VWROLFDUWHULDOSUHVVXUHE\FXႇVSK\JPRPDQRPHWHUHQG
V\VWROLFYROXPHIURP'DQGHQGGLDVWROLFYROXPHFRURQDU\ÀRZYHORFLW\UHVHUYHVWHS'LQOHIWDQWHULRUGHVFHQGLQJ
coronary artery (with pulsed wave-Doppler); 5) heart rate reserve (peak/rest heart rate) from EKG (step E); 6) mitral 
YDOYHUHJXUJLWDWHÀRZVWHS)DQG/927*VWHS*$%&'()*6(DOORZVDFRPSUHKHQVLYHDVVHVVPHQWRILQGXFLEOH
ischemia (A), lung water (B), myocardial systolic and diastolic function (C), coronary microcirculation (D), autonomic 
function (E), mitral regurgitation (F) and intraventricular obstruction (G). Yesterday SE used LVOTG for HCM with a 
RQH¿WVDOODSSURDFK6(7RGD\6(PD\H[SORLWLWVXQVXUSDVVHGYHUVDWLOLW\WRXQPDVNGLႇHUHQWSDWKRSK\VLRORJLFDOPH-
chanisms and potential therapeutic targets in a personalized and comprehensive approach to HCM.
/LVWRIDEEUHYLDWLRQV
CAD: coronary artery disease; ESC: European Society of Cardiology; HCM: hypertrophic cardiomyopathy; HRR: heart rate 
UHVHUYH/9OHIWYHQWULFOH/9272OHIWYHQWULFXODURXWÀRZWUDFWREVWUXFWLRQ5:0$UHJLRQDOZDOOPRWLRQDEQRUPDOLWLHV6$0
systolic anterior motion; SE: stress echocardiography
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most com-
mon monogenic disease of the myocardium, with 1:500 
prevalence in the general population worldwide, al-
WKRXJKRIWHQPLVGLDJQRVHGRUQHJOHFWHG+&0LVGH¿-
ned by the presence of increased left ventricular (LV) 
ZDOOWKLFNQHVVPPE\DQ\LPDJLQJPRGDOLW\LQRQH
or more LV myocardial segments that is not solely exp-
lained by abnormal loading conditions, and occurs in 
the absence of other detectable causes (1). A lower 
WKUHVKROG IRU /9 WKLFNQHVV LH  PP LV DGRSWHG
LQ ¿UVWGHJUHH UHODWLYHV RI SDWLHQWV ZLWK XQHTXLYRFDO
disease. Clinical diagnosis is customarily made with 
two-dimensional echocardiography by detection of inc-
reased LV wall thickness, usually in the presence of a 
small LV cavity, after suspicion has been raised by the 
FOLQLFDOSUR¿OHRUDVDSDUWRIVFUHHQLQJ ,QPRVWSDWL-
ents, HCM is caused by mutations in genes encoding 
contractile proteins of the cardiac sarcomere, Z-disk 
and intracellular calcium handling pathways. In over 
one-third of patients, however, the genetic basis of the 
disease remains unresolved (2).
HCM is often characterized by a stable and uneventful 
clinical course, and may be diagnosed late in life. How-
ever, about 50% of patients experience symptoms, and 
15% progress towards LV dysfunction and heart failure, 
including 5% ultimately developing end-stage disease. In 
addition, the condition is associated with a 0.5-1% annual 
risk of sudden cardiac death (2). Prior history of cardiac 
arrest is an obvious indicator of risk representing a clear-
FXWLQGLFDWLRQIRUWKHLPSODQWDEOHFDUGLRYHUWHUGH¿EULOOD-
tor (2). In primary prevention, however, arrhythmic risk 
prediction proves extremely challenging, due to the low 
event rate and low positive predictive accuracy of risk fa-
FWRUVLGHQWL¿HGWRGDWH&XUUHQWUHFRPPHQGDWLRQVRIWKH
European Society of Cardiology (ESC) include individual 
multiparametric assessment of annual sudden death risk 
score comprising age, family history of sudden death, 
personal history of unexplained syncope, left atrial dia-
PHWHUPD[LPDOZDOOWKLFNQHVVDQG/9RXWÀRZJUDGLHQWV
(at rest or during Valsalva) with baseline transthoracic 
echocardiography (1). Resting echocardiography with 
serial evaluations over time provides additional markers 
of high risk such as progressive wall thinning, declining 
systolic function, the presence of LV apical aneurysms, 
VHYHUHPLWUDO LQVXႈFLHQF\DQG UHVWULFWLYH/9¿OOLQJSDW-
tern (3). In all patients undergoing septal alcohol abla-
tion, intracoronary contrast echocardiography is recom-
mended to ensure correct localization of alcohol (1).
Stress echo in guidelines and  
recommendations
For decades, exercise was considered a strict contrain-
dication to exercise testing, for the fear of hemodynamic 
catastrophes. It is now established that a resting evalua-
tion cannot adequately represent the dynamic changes 
occurring during exercise in HCM patients, whose functi-
onal features are very heterogeneous from patient to pa-
tient (4), may vary in the same patient from rest to stress, 
DQGDUH VWULNLQJO\ DႇHFWHGE\ WKHUDSHXWLF LQWHUYHQWLRQV
(5). Therefore, according to recent 2017 joint recommen-
dations of European Association of Cardiovascular Ima-
ging-American Society of Echocardiography societies 
on stress echo beyond coronary artery disease, “exerci-
se SE is safe and commonly used especially in patients 
with equivocal symptoms, to determine functional capa-
city prior to a corrective therapeutic procedure, and for 
LQGLYLGXDOULVNVWUDWL¿FDWLRQ ´,QWKH(6&JXLGHOLQHV
on HCM, exercise SE is recommended in symptomatic 
patients if bedside manoeuvres fail to induce LVOTO 
PP+JDQGLVUDWHGDVFODVV,,D³VKRXOGEHFRQVL-
dered”), level of evidence B (“data derived from a single 
randomized clinical trial or large non-randomized studi-
es”). The recommendation is class II b (“may be consi-
dered”), level of evidence C (“consensus of opinion of 
the experts and/or small studies, retrospective studies, 
registries”), in asymptomatic patients. Other useful infor-
mation beyond the LVOTO can be obtained during SE, 
since – according to 2017 recommendations – “abnor-
mal blood pressure response to exercise, blunted systo-
lic and diastolic reserve, and worsened MR are associa-
ted with poor exercise capacity and outcome. SE is not 
indicated when a gradient >50 mmHg is present at rest”. 
The recommended stress is exercise with standing, sit-
ting or semi-supine position. Gradients are higher in the 
post-exercise standing position or in post-prandial exer-
cise, in physiological conditions when preload decrea-
ses. All these information’s represent a substantial cont-
ULEXWLRQWRFOLQLFDOPDQDJHPHQWDQGULVNVWUDWL¿FDWLRQ
According to an expert consensus of European Asso-
ciation of Cardiovascular Imaging in 2015, “SE can be 
XVHGIRUIXQFWLRQDOLPDJLQJLQ+&0ZLWKFRURQDU\ÀRZ
reserve assessment on the left anterior descending ar-
tery with concomitant wall motion analysis which pro-
vides diagnostic and prognostic information and may 
allow the distinction between obstructive epicardial co-
ronary disease and microvascular ischemia”. In fact, 
PLFURYDVFXODU DQJLQD LV LGHQWL¿HGE\ WKH FRPELQDWLRQ
of normal regional wall motion and blunted coronary 
ÀRZ UHVHUYHZKLOHREVWUXFWLYHHSLFDUGLDO&$'VKRZV
DUHGXFHGÀRZUHVHUYHDVVRFLDWHGZLWK5:0$$F-
cording to 2017 recommendations, vasodilation is the 
SUHIHUUHGPRGDOLW\ IRU WKHHYDOXDWLRQRIFRURQDU\ÀRZ
velocity reserve (7).
Stress echo beyond guidelines:  
the ABCDEFG protocol
In analogy with the standard state-of-the-art protocol 
ABCDE used and disseminated in the Stress echo 
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2020 study for the comprehensive functional testing of 
patients with suspected or known CAD and/or heart fa-
ilure (7, 8, 9), the most comprehensive protocol adap-
ted to the complexity and heterogeneity of HCM pati-
ents can be schematized as the ABCDEFG protocol. 
Each step of the stress echo evaluation corresponds to 
DGLႇHUHQWSDWKRSK\VLRORJLFDOWDUJHWLQ+&07DEOH 
The assessment is ideally performed during exercise, 
but at least for some parameters the same evaluation 
IRULQVWDQFHFRURQDU\ÀRZYHORFLW\UHVHUYHZLWKYDVR-
dilator stress) can be best performed during pharma-
cological testing when exercise is not feasible or has 
contraindications or simply too technically demanding. 
,Q WKHRU\ HDFK SDUDPHWHU KDV D GLႇHUHQW SDWKRSK\-
VLRORJLFDO WDUJHW DQG WKHUHIRUH D GLႇHUHQW WKHUDSHXWLF
counterpart. We currently miss the supportive evidence 
necessary to adopt a tailored SE-guided approach, but 
WKHH[LVWLQJGDWDDOUHDG\FKDOOHQJHWKHRQH¿WVDOODSS
roach which does not incorporate in decision-making 
the tremendous functional heterogeneity of the disease 
also mirrored by the heterogeneity of functional respon-
ses during SE.
A for regional wall motion abnormalities
Chest pain is a frequent symptom in HCM, and angio-
graphically assessed coronary artery disease (CAD) is 
found in about 20% of patients and is associated with an 
increased mortality. Many HCM patients with chest pain 
do not show epicardial disease, and their symptoms are 
likely due to microvascular disease. Perfusion changes 
can be present during stress scintigraphy and are lin-
NHGWRPLFURYDVFXODUGLVHDVHZLWKDSRRUVSHFL¿FLW\IRU
the detection of underlying epicardial CAD. For the pur-
SRVHVRIQRQLQYDVLYHLGHQWL¿FDWLRQRIFRQFRPLWDQW&$'
regional wall motion abnormalities (RWMA) in HCM pa-
WLHQWVDUHVXEVWDQWLDOO\PRUHVSHFL¿FWKDQSHUIXVLRQDE-
normalities and ST-segment depression, but also may 
VXႇHU IURP IDOVH SRVLWLYH UHVSRQVHV HVSHFLDOO\ LQ SUH-
sence of marked hypertrophy (10, 11). Therefore, a ne-
gative test for RWMA is useful for excluding functionally 
VLJQL¿FDQW&$'RULQ\RXQJHUSDWLHQWVWXQQHOLQJRIWKH
left anterior descending coronary artery, but a positive 
test is less useful for including a CAD and indicating an 
ischemia-driven revascularization. In patients with chest 
pain and positive SE for inducible RWMA, a noninvasive 
coronary computed angiography is indicated prior to re-
ferring the patient to ischemia-driven revascularization. 
RWMA occur in 6% of HCM patients and are a strong 
predictor of adverse outcome even in absence of under-
lying coronary artery disease (12, 13, 14).
%IRU%OLQHV
B-lines (also known as ultrasound lung comets) are a 
pre-clinical and pre-radiological sign of pulmonary con-
gestion assessed with lung ultrasound (15). Their ap-
pearance during stress indicates an acute backward 
KHDUW IDLOXUH ZKLFK PD\ KDYH GLႇHUHQW RULJLQV IURP
excessive afterload mismatch to diastolic dysfunction, 
DFXWHIXQFWLRQDOPLWUDOLQVXႈFLHQF\LQGXFLEOHLVFKHPLD
and RWMA (16). All these factors can come into play 
during stress in HCM patients. Diastolic reserve is usu-
ally assessed during SE with E/e' and systolic pulmo-
nary arterial pressure from tricuspid regurgitant jet, both 
considerably less feasible than B-lines during stress. 
When tricuspid regurgitant jet is absent, the accelera-
WLRQ WLPHRI WKHSK\VLRORJLFV\VWROLFSXOPRQDU\ÀRZ LV
a reasonable alternative. With increasing pulmonary 
pressures, acceleration time shortens when tricuspid 
jet velocity rises (17). B-lines are much easier to obtain 
and to analyze, and are also feasible in all patients in <1 
PLQXWHZLWKWKHVLPSOL¿HGVLWHVFDQ&RQFHSWXDO\-
O\WKH\IRFXVRQSXOPRQDU\FRQJHVWLRQGLႇHUHQWO\IURP
(H
PHDVXULQJ/9¿OOLQJDQGV\VWROLFSXOPRQDU\DUWHULDO
pressure assessing systemic hemodynamic conges-
tion. The appearance of B-lines is linearly, closely and 
negatively correlated with maximal oxygen consump-
tion on cardiopulmonary testing in heart failure patients 
DQGPD\XVHIXOO\LQWHJUDWHWKHSURJQRVWLFSUR¿OLQJ
of the patient, possibly indicating a personalized SE-
gui ded approach to lung decongestion therapy. Diure-
tics are generally considered contraindicated in HCM 
since they may induce dehydration which may induce 
TABLE 1. Clinically relevant information derived from stress echocardiography in HCM
Step Target Evidence level Possible examples of Management  
implications
A-wall motion  
abnormality 
Myocardial ischemia Guidelines Revascularization when CAD present with angina/
dyspnea
B: B-lines Pulmonary congestion Preliminary data Decongestion therapy in dyspnea?
C: Contractile reserve Left ventricular function Preliminary data Molecular anti-myosin therapy when increased?
D: Doppler Coronary microcirculation Expert consensus Cholesterol lowering drugs at LDL-C < 55 mg/dL?
E: EKG-based HRR Cardiac autonomic function Preliminary data Rate responsive atrial pacing?
F: Flow of MR Mitral valve dysfunction Expert consensus MV replacement when myectomy not enough?
G: Gradient in LVOTO LV obstruction Guidelines Beta-blockers in symptomatic, myectomy/myotomy 
in severely symptomatic refractory to medical therapy
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worsening of obstruction. It is however accepted that 
they can be used in HCM patients with dyspnea and 
pulmonary congestion (19). The observation of B-lines 
might eventually drive a more personalized use of diu-
retics in selected patients showing moderate to severe 
pulmonary congestion at rest or during stress.
&IRUFRQWUDFWLOHUHVHUYH
Contractile function is especially important in HCM pati-
HQWVDQGLVEHWWHUGH¿QHGZLWKORDGLQGHSHQGHQWIRUFH
(which also incorporates the value of LVOTG at rest and 
peak stress) rather than with ejection fraction (20, 21). 
At initial stages of HCM, the peculiar pattern is a nor-
mal-increased value of baseline ejection fraction, with a 
blunted increase of force during stress, associated with 
downregulation of SERCA-2 mRNA, resulting in alte-
red calcium handling which may contribute to reduced 
contractile reserve (22). About 1 of 4 to 5 uncomplica-
ted HCM patients have a defect in LV force reserve in 
spite of normal values of rest and stress ejection fracti-
on, and this defect is associated to a higher incidence 
RIDGYHUVHHYHQWV7KH LGHQWL¿FDWLRQRIFRQWUDFWL-
le state of the LV in HCM is especially relevant since 
in some mutations the earliest sign of the disease is a 
hyperdynamic contraction. For instance, the two most 
IUHTXHQWO\PXWDWHG+&0JHQHVHQFRGHȕFDUGLDFP\R-
sin heavy chain (MYH7) and myosin-binding protein 
C (MYBPC3).Young carriers of either MYH7 or MYB-
PC3 mutation have shown hyperdynamic contraction 
and impaired relaxation that precede the appearance 
of myocardial hypertrophy. A small molecule, MYK-
461, reduces contractility by decreasing the adenosine 
triphosphatase activity of the myosin heavy chain. The 
early, chronic administration of MYK-461 suppresses 
the development of left ventricular hypertrophy, cardi-
RP\RF\WH GLVDUUD\ DQGP\RFDUGLDO ¿EURVLV LQGLFDWLQJ
that hyperdynamic contraction is essential for HCM pa-
thobiology (24). The possibility of incorporating a simp-
le and reproducible biomarker of LV contractility such 
as force in the SE assessment of HCM seems especi-
ally attractive as new molecular therapies of contracti-
lity are now being tested in clinical studies.
'IRU'RSSOHUEDVHGFRURQDU\ÁRZYHORFLW\
reserve
Symptoms and signs of myocardial ischemia are often 
found in patients with HCM, in the presence of angi-
RJUDSKLFDOO\ QRUPDO FRURQDU\ DUWHULHV UHÀHFWLQJPLF-
rovascular disease exacerbated by myocardial hypert-
rophy and dynamic LV obstruction (1, 2). Myocardial 
ischemia is primarily due to extensive remodeling of the 
intramural coronary arterioles and blunted coronary 
artery reserve, occurring not only in the hypertrophied 
septum, but also in the less hypertrophied left ventri-
cular free wall. Microvascular ischemia is believed to 
contribute to the most severe manifestations of HCM 
including ventricular arrhythmias, sudden death and 
progressive left ventricular remodeling, and the degree 
of microvascular dysfunction is an independent predic-
tor of long-term deterioration and death from cardiovas-
FXODUFDXVHV&RURQDU\ÀRZYHORFLW\UHVHUYHLVUHGXFHG
LQDERXWRQHWKLUGRI+&0SDWLHQWVDV¿UVWGHVFULEHG
with accurate but costly positron emission tomography 
imaging me thods (25). The measurement is equally 
reliable and substantially simpler with Doppler echocar-
diography on mid-distal left anterior descending artery 
with vasodilators. The feasibility is >95% in general po-
pulation (9), and higher in HCM since the thick septum, 
the large coronary diameter and the increased resting 
ÀRZPDNHWKHGHWHFWLRQDQGVDPSOLQJRIFRURQDU\ÀRZ
faster and easier. As in other models of microvascu-
lar disease, such as cardiac syndrome X or arterial hy-
pertension (26, 27), simple ST-segment changes are 
frequently elicited during vasodilator stress in HCM pa-
WLHQWVUHSUHVHQWLQJUHGXFHGÀRZUHVHUYHDQGWUXHVX-
bendocardial underperfusion (28) and are associated 
with worse outcome (29, 30). Of note, the absence of 
RWMA does not necessarily contradict the ischemic na-
ture of chest pain and ST-segment depression in HCM 
patients. Rather, because of the largely subendocardial 
nature of ischemia, as well as the considerable LV wall 
thickness, the degrees of transmural involvement are 
less likely to reach the critical mass of ischemic tissue 
needed to determine wall motion and thickening abnor-
malities. The presence and degree of impairment of 
CFVR is largely unrelated to the presence and degree 
of left ventricular hypertrophy, although more pronoun-
ced in presence of LVOTO and relieved by myectomy 
(31). The reduction of CFVR shows a striking prognos-
tic value, clearly superior to LVOTO (32, 33).
The presence of a dominant phenotype with coronary 
microvessel dysfunction could suggest a therapy with 
beta-blockers and calcium-antagonists, an aggressive 
therapy of risk factors toxic for microcirculation such as 
glycemia (with insulin) or LDL-cholesterol (with statin or 
PCSK9-inhibitors), or possibly a selective therapeutic 
intervention with drugs acting on coronary microcircu-
ODWLRQDQGNQRZQWRLPSURYHFRURQDU\ÀRZUHVHUYH
in HCM (35).
(IRU(.*EDVHGKHDUWUDWHUHVHUYH
Even in the stress imaging era, non-imaging information 
VLPSO\EDVHGRQROGIDVKLRQHG(.*DQGFXႇVSK\JPR-
manometer can supply surprising pathophysiological 
and prognostic information and should be incorporated 
in the analysis and reporting of stress response. The 
3 main categories of information, additive and comp-
lementary to imaging, relate to systolic blood pressure 
response, inducible arrhythmias and heart rate respon-
se.
$EQRUPDOEORRGSUHVVXUHUHVSRQVHWRH[HUFLVHLVGH¿-
ned as exercise-induced hypotension (any decrease in 
systolic blood pressure below baseline in the absence 
of an initial rise with exercise, or a sustained decrease 
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of >20 mmHg during exercise following an initial rise) 
or failure to increase blood pressure (a systolic blood 
pressure rise of less than 20 mmHg from baseline) (1). 
Abnormal blood pressure response to exercise is ob-
served up to one-quarter of HCM patients, and is be-
lieved to identify hemodynamic instability secondary to 
LVOTO, diastolic dysfunction, microvascular ischemia 
and inappropriate peripheral vasodilatation, represen-
ting an independent predictor of sudden cardiac death 
(2). Whether therapeutic interventions such as surgical 
myectomy, alcohol septal ablation or pharmacological 
therapy may consistently resolve abnormal blood pres-
sure response, and whether this in turn may translate 
LQWRDVXUYLYDOEHQH¿WLVDV\HWXQUHVROYHG([HUFLVHLQ-
duced hypotension is an indication for interruption of 
stress testing, and may require positioning the patient 
in the supine or Trendelemburg position when sympto-
matic.
Exercise induced ventricular arrhythmias are uncom-
mon in HCM patients but, when present, predict major 
arrhythmic events. The clinical relevance of ventricu-
lar arrhythmias in HCM is inversely related to age, and 
should be considered with particular suspicion in the 
pediatric/adolescent age group (1, 2).
Heart rate reserve (HRR) is easily measured from 1 
lead EKG (present by protocol in the echo monitor) as 
the peak/rest heart rate ratio. A blunted HRR (<1.80) is 
a marker of cardiac autonomic dysfunction and reduced 
sympathetic reserve (36). Impairment of HRR is asso-
ciated with increased risk of cardiovascular outcomes 
and all-cause mortality in the general population, with 
independent value over inducible RWMA during SE 
with exercise (36), dobutamine (37) and dipyridamole 
(8). In HCM, a reduced HRR is associated with a lower 
peak oxygen consumption at cardiopulmonary testing, 
KLJKHUGHJUHHRIP\RFDUGLDO ¿EURVLVZLWKGHOD\HGHQ-
hancement with cardiovascular magnetic resonance 
and worse outcome (38). At least in theory, chronot-
ropic incompetence of HCM might be selectively cor-
rected with atrial pacing.
)IRUIXQFWLRQDOPLWUDOUHJXUJLWDWLRQ
/9 RXWÀRZ REVWUXFWLRQ LV D SDWKRSK\VLRORJLFDO FRQV-
piracy caused by the concomitance of marked mitral 
OHDÀHWHORQJDWLRQK\SHUFRQWUDFWLOHVPDOORUQRUPDOVL-
zed LV, abnormally positioned papillary muscles, small 
/9 RXWÀRZ WUDFW GLPHQVLRQV DQG DEQRUPDOO\ GLUHFWHG
DQWHURJUDGHÀRZLQV\VWROHGXHWRVHSWDOK\SHUWURSK\
leading to systolic anterior motion (SAM) of the mitral 
valve. SAM is in turn associated with variable degrees 
of functional (SAM-related) mitral regurgitation, due to 
ORVVRI OHDÀHWFRDSWDWLRQZKLFK LVPLGWRODWHV\VWROLF
and infero-laterally oriented (1). In the elderly, poste-
ULRU PLWUDO DQQXOXV FDOFL¿FDWLRQ DQWHURSRVLWLRQ RI WKH
mitral apparatus and sigmoid septal morphology with 
decreased septal-aortic angle increase the likelihood of 
SAM and obstruction, which may develop in previously 
unobstructed patients. Due to its dynamic nature, the 
severity of mitral regurgitation varies with the degree 
RI/9272PD\LQFUHDVHVLJQL¿FDQWO\GXULQJHႇRUWDQG
an exercise-induce at least moderate mitral regurgita-
tion represents a main determinant of symptoms and 
prognosis (39). In many cases, surgical myectomy (or 
DOFRKROVHSWDODEODWLRQPD\EHVXႈFLHQWWRFRUUHFW05
which decreases with the reduced obstruction. How-
ever, since it can be also primarily due to morphologic 
FKDQJHVVXFKDVHORQJDWLRQRIPLWUDO OHDÀHWVRUSDSLO-
ODU\PXVFOHDEQRUPDOLWLHVLQVSHFL¿FLQVWDQFHVFRQFR-
mitant MV repair or novel percutaneous interventions 
may be required (1).
*IRULQWUDYHQWULFXODUSUHVVXUH*UDGLHQW
Intraventricular obstruction is an additional mechanism 
of ischemia, determining a disproportionate increase in 
R[\JHQGHPDQGDQGUHGXFWLRQ LQVXEHQGRFDUGLDOÀRZ
supply due to increased extravascular resistances (41). 
Most HCM patients have the propensity to develop int-
raventricular gradients under resting or physiologically 
provocable conditions. Such dynamic obstruction ge-
QHUDOO\RFFXUVDWWKH/9RXWÀRZSURGXFHGE\6$0RI
the mitral valve causing ventricular septal contact.
'\QDPLFREVWUXFWLRQPD\RFFXUDWGLႇHUHQWVLWHVEHVL-
des the LVOT, including the LV mid-ventricle (due to in-
terposition and septal contact of the anterior papillary 
muscle) and the RVOT (due to a sphincter-like mecha-
nism occurring at the level of the crista supraventricu-
laris) (42). Fixed, anatomic obstruction due to sub-aor-
tic membranes should be carefully excluded. Each 
of these mechanism should be systemically asses-
VHGVLQFHPDQDJHPHQWVWUDWHJLHVPD\GLႇHUSDUWLFX-
larly when interventions aimed at relieving LVOTO are 
considered (1, 2). Dynamic assessment of LVOTO (at 
rest, during bedside manoeuvers and exercise) holds 
important prognostic information and plays a pivotal 
role for the assessment of symptoms (2, 3).
%\FRQYHQWLRQ/9272LVGH¿QHGDVDQLQVWDQWDQHRXV
SHDN'RSSOHU /9 RXWÀRZ WUDFW SUHVVXUH JUDGLHQW 
mmHg at rest or during physiological provocation (i.e.: 
Valsalva manoeuver, standing and isotonic exercise). 
$JUDGLHQWRIPP+JLVXVXDOO\FRQVLGHUHGWKHWK-
reshold at which LVOTO becomes hemodynamically 
important and invasive treatment may be appropriate 
(2, 3). Up to one-third of patients have obstruction at 
rest (peak instantaneous gradient > 30 mmHg), another 
third have labile, physiologically provoked gradient (<30 
mmHg at rest and physiologically provoked gradient 
>30 mmHg) and only one-third have true non-obstruc-
tive forms (rest and physiologically provoked gradient 
< 30 mmHg) (41). Provokable gradients may characte-
ristically peak after cessation of exercise, due to the 
HႇHFWVRIWKHHQVXLQJIDOOLQSHULSKHUDOUHVLVWDQFH
Of note, while not all patients with HCM have LVOTO, it 
is also true that not all subjects with stress-induced gra-
GLHQWVDQG/9272KDYH+&06LJQL¿FDQWJUDGLHQWVFDQ
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be observed during exercise or dobutamine in patients 
with Syndrome X or hypertension, athletes, tako-tsubo 
syndrome, congenital heart diseases, following cardi-
ac valve surgery, or in acute myocardial infarction, and 
can be precipitated by dehydration, reduction in preload 
and LV cavity size and/or increase in LV contractility.
Technical issues and pitfalls
In the vast majority of HCM patients, stress testing 
can be performed safely, including those with elevated 
LVOTO at rest who have no history of hemodynamic 
LQVWDELOLW\RQHႇRUW ,Q IDFWZKLOH+&0KDV ORQJEHHQ
considered a relative contraindication to stress testing, 
it is now well established that echocardiography during 
physiological exercise has minimal risk when perfor-
med in a controlled, supervised environment (6). Ne-
vertheless, in a subset of HCM patients stress testing 
is not feasible or advisable, due inability to exercise, 
severe congestive symptoms (New York Heart Asso-
FLDWLRQFODVV,,,KHPRG\QDPLF LQVWDELOLW\DVVRFLDWHG
ZLWK/9272DWUHVWNQRZQHႇRUWLQGXFHGDUUK\WKPLDV
or severe comorbidities. Conversely, acoustic window 
quality is rarely a problem, given the young mean age 
of patients with HCM.
6LQFH PDQ\ IDFWRUV PD\ DႇHFW /9272 HYDOXDWLRQ D
standardized approach is essential in order to have 
PHDQLQJIXO DQG FRPSDUDEOH UHVXOWV DFURVV GLႇHUHQW
ODERUDWRULHV 'LႇHUHQW H[HUFLVH PRGDOLWLHV KDYH EHHQ
described in the literature, including semi-supine er-
gometer, treadmill (with image acquisition either du-
ring exercise or at peak and supine immediately after 
exertion) upright bicycle, with imaging during exercise, 
at peak upright and immediately after exertion, upright 
and supine. The semi-supine exercise is a reasonab-
le choice, although cardiac symptoms in these patients 
are noted most commonly when they are in the erect 
position, during or immediately after exertion (1). Sub-
VWDQWLDODJUHHPHQWEHWZHHQ WKHPDJQLWXGHRIRXWÀRZ
JUDGLHQWVPHDVXUHGDWWKH¿QDOVWHSRIWKHH[HUFLVHWHVW
in the upright position and those gradients obtained in 
the supine position immediately following cessation of 
exercise has been reported, with post-exercise supine 
gradients overestimating somewhat the upright gradi-
ents on the average of 5 mmHg for the study group (40). 
The timing of onset of obstruction was shown to dictate 
the degree to which exercise capacity was impaired in 
HCM patients with provokable gradients (40). The ESC 
guidelines suggest that “laboratories should develop 
DQGYDOLGDWHWKHLURZQSURWRFRODQGHQVXUHWKDWVWDႇDUH
properly trained in the procedure.” In an ideal setting, 
care should be given to assessing degree of obstruc-
tion, mitral regurgitation, diastolic dysfunction, RWMA 
DQGSXOPRQDU\SUHVVXUHVDWHDFKVWHS&RURQDU\ÀRZ
velocity reserve can be assessed during exercise or in 
a separate same-day session with vasodilator stress. 
Whatever the stress, HRR should be reported. A frequ-
HQWSLWIDOOGXULQJHႇRUWLQYROYHVWKHSRVVLELOLW\RIVDPS-
ling MR instead of intraventricular gradients. Therefore, 
the utmost care should be employed to avoid this sour-
ce of misinterpretation (6). B-lines by lung ultrasound 
are usually measured soon after the end of exercise, 
so not to interfere with other measurements (such as 
FIGURE 1. A working hypothesis: risk stratification with the ABCDEFG protocol. SE acts as a Newton's prism decoding the 
homogeneous white light of clinical presentation and resting transthoracic echocardiography findings in a spectrum of diffe-
rent responses and corresponding risks, when all parameters are normal (left side, green code, ABCDEFG negative) up to the 
extreme right when all parameters are abnormal (right side, red code, ABCDEFG positive)
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/9272RUPLWUDOLQVXႈFLHQF\RIFRURQDU\ÀRZYHORFLW\
in left anterior descending artery) that instantaneously 
change at exercise interruption. B-lines remain visible 
for some minutes and therefore they can be acquired 
LQWKH¿UVWPLQXWHDIWHULQWHUUXSWLRQRIH[HUFLVHZLWKRXW
VLJQL¿FDQWORVVRILQIRUPDWLRQ
Conclusion
HCM is a complex and heterogeneous disease with 
protean manifestations and the current unidimensional 
approach of SE mainly, if not exclusively, focused on 
LV obstruction does not exploit at the fullest the unique 
versatility of the technique. Its ubiquitous availability, 
low cost, radiation-free nature make SE ideally suited 
to be serially applied to HCM patients at all stages of 
disease and all ages of life to allow a comprehensive 
ULVNVWUDWL¿FDWLRQ LQ WKHVHFRPSOH[SDWLHQWV)LJXUH. 
SE provides a cinematographic, not only snapshot, 
description of the development, evolution and progres-
sion of the disease from its preclinical pre-hypertrophic, 
to hypertrophic-stable, up to late stages of adverse re-
modeling and obvious resting LV dysfunction. This is 
particularly important today, since HCM is discovered 
early and HCM-related causes of death are only a mi-
nority in adult patients, with cancer and CAD being the 
leading cause after the age of 60 (41). It is especially 
important to avoid damage and risk from cumulative io-
nizing radiation exposure, which can be substantial in 
these patients if scintigraphy, positron emission tomo-
graphy, coronary computed angiography and invasive 
angiography are used liberally (as done in the past) also 
at early age, leading to a substantial cumulative radia-
tion exposure directly and linearly linked to cancer risk 
(42, 43). Another potential problem is the cumulative 
HႇHFWVRIJDGROLQLXPSDUDPDJQHWLF FRQWUDVWDJHQWRI
special concern at young age and in patients repeating 
serial examinations over time as HCM patients often do 
HVSHFLDOO\ IRU WKH HYDOXDWLRQ RIP\RFDUGLDO ¿EURVLV D
known prognostic determinant (44). At least in princip-
le, SE has the potential to discriminate, at low cost and 
without any known long-term risk, the various functio-
nal components, providing an unprecedented amount 
of information ideally suited to be combined with clinical 
and genetic data in the methodological framework of 
network medicine (45) and eventually paving the way 
to a personalized treatment driven by pathophysiology.
('3LVUHFLSLHQWRIWKH(UDVPXVJUDQWIRUPHGLFDOVWX
GHQWVVSHQWLQ3LVDLQ$XJXVW$SULO
7KH$XWKRUVKDYHQRFRQÀLFWRILQWHUHVWWRGLVFORVH
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